Dave,
Roche already has an existing approved anti PD-L1, Tecentriq.
Doing about Us$3 billion a year with all the usual side effects and tox of a mAb. Would lend itself very well to combination. Could send a big shot across the bows of Keytruda.
Then add a combo with Perjeta another existing Roche drug also struggling to make headway.
And of course a combo with Herceptin.
Instantly improving existing sales over Us$10 billion a year with those 3 becoming" far safer, kinder, gentler" treatments and with greater efficacy.
LC has said many times, to paraphrase, " we will look to combine with the pharma whose existing pipeline fits best for combos to advance the B cell platform"
Roche is the standout, money ain't a problem.
And still the market has growing pains, blindly unaware how much closer this becomes.
- Forums
- ASX - By Stock
- Media Thread
Dave,Roche already has an existing approved anti PD-L1,...
-
-
- There are more pages in this discussion • 14,271 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMU (ASX) to my watchlist
|
|||||
Last
5.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $396.8M |
Open | High | Low | Value | Volume |
5.4¢ | 5.4¢ | 5.3¢ | $339.4K | 6.365M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
7 | 895592 | 5.3¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
5.4¢ | 672708 | 10 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 845592 | 0.053 |
21 | 2719942 | 0.052 |
37 | 3800174 | 0.051 |
70 | 5690066 | 0.050 |
16 | 2155346 | 0.049 |
Price($) | Vol. | No. |
---|---|---|
0.054 | 672708 | 10 |
0.055 | 2964674 | 13 |
0.056 | 2227496 | 13 |
0.057 | 1068065 | 8 |
0.058 | 725800 | 5 |
Last trade - 16.10pm 28/08/2024 (20 minute delay) ? |
Featured News
IMU (ASX) Chart |
The Watchlist
HAR
HARANGA RESOURCES LIMITED.
Peter Batten, MD
Peter Batten
MD
Previous Video
Next Video
SPONSORED BY The Market Online